Organovo Holdings (NYSEMKT:ONVO) rode the wave of 3-D printing hoopla to a listing on the New York Stock Exchange.  During 2013, the 3-D bioprinting company saw its shares more than quadruple. This year, however, has not been so kind -- with shares having lost about one-third of their value.

Being an investor -- as opposed to a trader -- means taking the long view when it comes to buying and selling stocks. That doesn't mean months or even a year, but at least three years. That's usually the bare minimum required to see whether or not your investment thesis plays out.

That being said, it's worth checking in with your holdings on a semiregular basis. With 2014 almost half way done, now seems like the perfect time to cover your bases. In the slideshow below, you'll see how Organovo got to where it has this year, and what you need to keep your eyes on for the rest of 2014.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Stoffel owns shares of Organovo Holdings. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers